The full name is "Shanghai Sailun Biotechnology Co., Ltd.", and its main business is the research, development, production and sales of preventive and therapeutic drugs for biotoxins and biosafety. In the field of snake wound treatment, the company's antivenom is independently produced and sold in China, which is original and unique. Up to now, no foreign pharmaceutical company has entered the market field of China, which has achieved independent control in the field of snake injury first aid in China. In the field of tetanus treatment, the company independently produced equine tetanus immunoglobulin (F (AB ′) 2) for preventing and treating tetanus; In the field of rabies treatment, the company's anti-rabies serum products are used for rabies prevention.
Issuance: the current market value of the enterprise is 268 1 100 million yuan, the new issue market value is 890 million yuan, the issue price is 33.03 yuan, the price-earnings ratio of the issue is 63.28, and the PE-TTM is 34.90x. The top subscription needs a market value of 75,000 yuan. Compared with biological products industry, PE-TTM is 60.4 1, Tiantan Bio-PE-TTM is 53.08x, Hualan Bio-PE-TTM is 27.29x, Laishi Bio-PE-TTM is 27.55x, Pailin Bio-PE-TTM is 50.54x, Weiguang Bio-PE-TTM is 32.63x. It accounts for about 40%, followed by anti-Agkistrodon halys. As no other enterprise in the industry produces anti-venom serum or horse immunoglobulin products, comparable enterprises can only choose similar biomedical enterprises.